Hydrocodone for cough in advanced cancer

Jade Homsi; Declan Walsh; Kristine A. Nelson; Susan B. Legrand; Mellar Davis

doi:10.1177/104990910001700512

Hydrocodone for cough in advanced cancer

Jade Homsi, Declan Walsh, Kristine A. Nelson, Susan B. Legrand, Mellar Davis

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Cough is a common symptom in advanced cancer. Hydrocodone is the antitussive of choice in our palliative medicine inpatient unit. We reviewed the pharmacy records for the use of hydrocodone for all cancer admissions to our unit from May 1996 to December 1998. Median treatment duration with hydrocodone was three days (range 1-18). Median maximum daily dose was 15 mg (range 5-100), and median total dose during the hospital stay was 32 mg (range 5-455). Lung cancer as a primary cancer site was strongly related to the use of hydrocodone. The highest median duration of treatment (five days) was for esophageal cancer and the highest median maximum daily dose (35 mg) and total dose (75 mg) were for treating kidney cancer. This retrospective review provides information regarding the use of hydrocodone on the palliative medicine unit of the Cleveland Clinic Foundation. Controlled trials are needed to evaluate the efficacy and safety of hydrocodone for cough in advanced cancer.

Original language	English (US)
Pages (from-to)	342-346
Number of pages	5
Journal	American Journal of Hospice and Palliative Medicine
Volume	17
Issue number	5
DOIs	https://doi.org/10.1177/104990910001700512
State	Published - Sep 2000

ASJC Scopus subject areas

General Medicine

Access to Document

10.1177/104990910001700512

Cite this

@article{a7bec867e69a4dc985217c4cb57e010b,

title = "Hydrocodone for cough in advanced cancer",

abstract = "Cough is a common symptom in advanced cancer. Hydrocodone is the antitussive of choice in our palliative medicine inpatient unit. We reviewed the pharmacy records for the use of hydrocodone for all cancer admissions to our unit from May 1996 to December 1998. Median treatment duration with hydrocodone was three days (range 1-18). Median maximum daily dose was 15 mg (range 5-100), and median total dose during the hospital stay was 32 mg (range 5-455). Lung cancer as a primary cancer site was strongly related to the use of hydrocodone. The highest median duration of treatment (five days) was for esophageal cancer and the highest median maximum daily dose (35 mg) and total dose (75 mg) were for treating kidney cancer. This retrospective review provides information regarding the use of hydrocodone on the palliative medicine unit of the Cleveland Clinic Foundation. Controlled trials are needed to evaluate the efficacy and safety of hydrocodone for cough in advanced cancer.",

author = "Jade Homsi and Declan Walsh and Nelson, {Kristine A.} and Legrand, {Susan B.} and Mellar Davis",

year = "2000",

month = sep,

doi = "10.1177/104990910001700512",

language = "English (US)",

volume = "17",

pages = "342--346",

journal = "American Journal of Hospice and Palliative Medicine",

issn = "1049-9091",

publisher = "SAGE Publications Inc.",

number = "5",

}

TY - JOUR

T1 - Hydrocodone for cough in advanced cancer

AU - Homsi, Jade

AU - Walsh, Declan

AU - Nelson, Kristine A.

AU - Legrand, Susan B.

AU - Davis, Mellar

PY - 2000/9

Y1 - 2000/9

N2 - Cough is a common symptom in advanced cancer. Hydrocodone is the antitussive of choice in our palliative medicine inpatient unit. We reviewed the pharmacy records for the use of hydrocodone for all cancer admissions to our unit from May 1996 to December 1998. Median treatment duration with hydrocodone was three days (range 1-18). Median maximum daily dose was 15 mg (range 5-100), and median total dose during the hospital stay was 32 mg (range 5-455). Lung cancer as a primary cancer site was strongly related to the use of hydrocodone. The highest median duration of treatment (five days) was for esophageal cancer and the highest median maximum daily dose (35 mg) and total dose (75 mg) were for treating kidney cancer. This retrospective review provides information regarding the use of hydrocodone on the palliative medicine unit of the Cleveland Clinic Foundation. Controlled trials are needed to evaluate the efficacy and safety of hydrocodone for cough in advanced cancer.

AB - Cough is a common symptom in advanced cancer. Hydrocodone is the antitussive of choice in our palliative medicine inpatient unit. We reviewed the pharmacy records for the use of hydrocodone for all cancer admissions to our unit from May 1996 to December 1998. Median treatment duration with hydrocodone was three days (range 1-18). Median maximum daily dose was 15 mg (range 5-100), and median total dose during the hospital stay was 32 mg (range 5-455). Lung cancer as a primary cancer site was strongly related to the use of hydrocodone. The highest median duration of treatment (five days) was for esophageal cancer and the highest median maximum daily dose (35 mg) and total dose (75 mg) were for treating kidney cancer. This retrospective review provides information regarding the use of hydrocodone on the palliative medicine unit of the Cleveland Clinic Foundation. Controlled trials are needed to evaluate the efficacy and safety of hydrocodone for cough in advanced cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034285980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034285980&partnerID=8YFLogxK

U2 - 10.1177/104990910001700512

DO - 10.1177/104990910001700512

M3 - Article

C2 - 11886059

AN - SCOPUS:0034285980

SN - 1049-9091

VL - 17

SP - 342

EP - 346

JO - American Journal of Hospice and Palliative Medicine

JF - American Journal of Hospice and Palliative Medicine

IS - 5

ER -

Hydrocodone for cough in advanced cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this